ArticleFluids and barriers of the CNS2026
2-Hydroxypropyl-β-cyclodextrin accesses acute and subacute infarcts in a mouse model of ischemic stroke.
Article in Fluids and barriers of the CNS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ischemic stroke is a leading cause of mortality and long-term disability worldwide, with limited pharmacological interventions available. 2-hydroxypropyl-β-cyclodextrin (HPβCD), a cyclic oligosaccharide approved for use as an excipient in pharmaceutical formulations, has demonstrated therapeutic potential in preclinical models of ischemic stroke by attenuating immune cell and lipid droplet accumulation in infarcts. However, the ability of HPβCD to penetrate ischemic brain tissues remains a critical determinant of its efficacy. The present study aimed to (1) assess the penetration and distribution of FITC-HPβCD within acute and subacute infarcts, which are sites of persisting blood-brain barrier (BBB) impairment, and (2) validate the accumulation of FITC-HPβCD in previously identified target organs, including the kidneys, liver, and spleen, using an aged (15-month-old) male mouse model of ischemic stroke induced by distal middle cerebral artery occlusion. We determined that FITC-HPβCD exhibits widespread systemic dissemination within 30 min after subcutaneous administration and is primarily eliminated via renal excretion. Notably, FITC-HPβCD selectively accumulated in the ipsilateral (i.e., infarcted) hemisphere 24 h and 1 week after ischemic stroke, indicating that ischemia enhances the penetration of FITC-HPβCD into the brain. These results provide valuable insights into the therapeutic potential of HPβCD as a treatment for ischemic stroke and inform strategies for optimizing drug delivery to the brain in cerebrovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.